A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

ClinicalTrials.gov ID: NCT06499285

Public ClinicalTrials.gov record NCT06499285. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 16, 2026, 12:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elritercept (KER-050) for the Treatment of Transfusion-Dependent Anemia in Adult Participants With Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) (RENEW)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also check on how safe elritercept is and how well it is tolerated.

Study identification

NCT ID: NCT06499285
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Takeda; Industry
Enrollment: 225 participants

Conditions and interventions

Conditions

Myelodysplastic Syndromes

Interventions

Elritercept Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 6, 2025 (Actual)
Primary completion: May 1, 2028 (Estimated)
Completion: May 1, 2032 (Estimated)
Last update posted: Oct 8, 2026

2025 – 2032

United States locations

U.S. sites: 25
U.S. states: 15
U.S. cities: 24

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Recruiting
Los Angeles Cancer Network	Glendale	California	91206	Recruiting
UC San Diego Moores Cancer Center	La Jolla	California	92037	Recruiting
Smilow Cancer Hospital at Yale-New Haven	New Haven	Connecticut	06511	Recruiting
University of Miami Hospital and Clinics	Miami	Florida	33136	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
ILCC. Illinois Cancer Centers	Peoria	Illinois	61645	Recruiting
Norton Cancer Institute	Louisville	Kentucky	40207	Recruiting
Ghattas Oncology	Monroe	Louisiana	71201	Not yet recruiting
Maryland Oncology Hematolofy	Columbia	Maryland	21044	Recruiting
MidAmerica Cancer Care	Kansas City	Missouri	64132	Recruiting
Comprehensive Cancer Centers of Nevada	Henderson	Nevada	89169	Recruiting
Clinical Research Alliance NY	Westbury	New York	11590	Recruiting
Novant Health-Cancer Institute	Winston-Salem	North Carolina	27013	Recruiting
Gabrail Cancer Center Research	Canton	Ohio	44718	Recruiting
Cleveland Clinic - Cleveland	Cleveland	Ohio	44195	Recruiting
Tennessee Cancer Specialists	Knoxville	Tennessee	37909	Recruiting
Vanderbilt University Medical Center	Nashville	Tennessee	37232	Recruiting
Texas Oncology Northeast Texas	Denison	Texas	75020	Recruiting
U.T. MD Anderson Cancer Center, Division of Cancer Medicine	Houston	Texas	77030	Recruiting
LUMI Research	Houston	Texas	77090	Recruiting
Epic Medical Research	Red Oak	Texas	75154	Not yet recruiting
Texas Oncology Gulf Coast	The Woodlands	Texas	77380	Recruiting
Tranquil Research	Webster	Texas	77598-4085	Recruiting
Epic Care Emeryville	Issaquah	Washington	98029	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 157 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06499285, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 8, 2026 · Synced Oct 16, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT06499285 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →